Directions for optimizing the organization of long-term anticoagulant treatment
Закрыть
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
107 2
Ultima descărcare din IBN:
2024-03-18 09:45
Căutarea după subiecte
similare conform CZU
616-085.273.53 (1)
Патология. Клиническая медицина (6965)
SM ISO690:2012
SUMARGA, Natalia, BELÎI, Adrian. Directions for optimizing the organization of long-term anticoagulant treatment. In: Moldovan Medical Journal, 2023, nr. 2(66), pp. 36-40. ISSN 2537-6373. DOI: https://doi.org/10.52418/moldovan-med-j.66-2.23.06
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Moldovan Medical Journal
Numărul 2(66) / 2023 / ISSN 2537-6373 /ISSNe 2537-6381

Directions for optimizing the organization of long-term anticoagulant treatment

DOI:https://doi.org/10.52418/moldovan-med-j.66-2.23.06
CZU: 616-085.273.53

Pag. 36-40

Sumarga Natalia, Belîi Adrian
 
”Nicolae Testemițanu” State University of Medicine and Pharmacy
 
 
Disponibil în IBN: 27 decembrie 2023


Rezumat

Background: In this study the organization of long-term anticoagulant treatment has been evaluated to estimate whether clinical practice is in accordance with current recommendations for optimal use and effective control of oral anticoagulant (OAC) treatment. Material and methods: Mixed (quantitative and qualitative), transversal, descriptive, selective study. Samples: quantitative study – 394 adult patients, eligible for anticoagulant treatment; qualitative study – 39 family doctors. Results: The rate of use of OAC treatment is 68%. The period from the diagnosis of the disease to the initiation of OAC treatment lasted one month or more in 59.1% of patients. 60.6% of patients do not have sufficient knowledge regarding the treatment of OAC. The high price is the most important barrier to direct oral anticoagulant administration (91.1%). Patients’ satisfaction with OAC treatment control is low, mainly for vitamin K antagonists (59.8%). 75.5% of respondents claim that OAC treatment control and management is poor. 40.3% do not perform safe therapeutic International Normalized Ratio control, and 54.7% are not in the optimal therapeutic range. Conclusions: The main barriers to adherence to OAC treatment: the burden of regular monitoring of blood parameters, perceived concern about complications, limited access to laboratory tests and specialist doctors, insufficient information about anticoagulation, and deficiencies in communication with medical staff. There is limited conviction, and uncertainty persists in the initiation and monitoring of OAC treatment by family doctors.

Cuvinte-cheie
control of anticoagulant treatment, Warfarin management, oral anticoagulants, atrial fibrillation